{{Drugbox | Verifiedfields = changed | verifiedrevid = 464197136 | IUPAC_name = N,N-diethyl-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine | image = Pamaquine.svg | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = | CAS_number = 491-92-9 | ATC_prefix = none | ATC_suffix = | PubChem = 10290 | DrugBank_Ref = | DrugBank = | ChemSpiderID_Ref = | ChemSpiderID = 9868 | UNII_Ref = | UNII = 99QVL5KPSU | ChEMBL_Ref = | ChEMBL = 472698 | C=19 | H=29 | N=3 | O=1 | smiles = O(c1cc(NC(C)CCCN(CC)CC)c2ncccc2c1)C | StdInChI_Ref = | StdInChI = 1S/C19H29N3O/c1-5-22(6-2)12-8-9-15(3)21-18-14-17(23-4)13-16-10-7-11-20-19(16)18/h7,10-11,13-15,21H,5-6,8-9,12H2,1-4H3 | StdInChIKey_Ref = | StdInChIKey = QTQWMSOQOSJFBV-UHFFFAOYSA-N }}Pamaquine''' is an 8-aminoquinoline drug formerly used for the treatment of malaria. It is closely related to primaquine. Synonyms Plasmochin Plasmoquine Plasmaquine Uses Pamaquine is effective against the hypnozoites of the relapsing malarias (P. vivax and P. ovale''); and unlike primaquine, it is also very effective against the erythrocytic stages of all four human malarias. One small clinical trial of pamaquine as a causal prophylactic was disappointing (whereas primaquine is an extremely effective causal prophylactic). Pamaquine is more toxic and less efficacious than primaquine; therefore, pamaquine is no longer routinely used, and of the two, only primaquine is currently recommended by the World Health Organization. Adverse effects Like primaquine, pamaquine causes haemolytic anaemia in patients with G6PD deficiency. Patients should therefore always be screened for G6PD deficiency prior to being prescribed pamaquine. History Pamaquine was the second synthetic antimalarial drug to be discovered (after methylene blue). It was synthesised by Schulemann, Schoenhoeffer and Wingler in 1924. In 1926, Roehl demonstrated that pamaquine was effective in treating malaria in birds, and introduced it into use in humans. Its development is of interest in the history of pharmacotherapy because it was one of the early victories in validating the potential of applying organic chemistry to the synthesis of chemicals that would fight infections with good specificity while presenting adverse effect profiles small enough that benefit would outweigh harm, relative to the contemporary alternative of little to no efficacious treatment for many debilitating diseases. In other words, it expanded the evidence that the hope for great potential of antimicrobial chemotherapy shown by Paul Ehrlich and others was worth pursuing with